Literature DB >> 23197687

In reference to WKA Yung (Neuro-oncology 2012; 14:1115).

Erwin Krauskopf.   

Abstract

Mesh：

Year:  2012        PMID： 23197687      PMCID： PMC3548590          DOI： 10.1093/neuonc/nos310

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  5 in total

1.  The top-ten in journal impact factor manipulation.

Authors:  Matthew E Falagas; Vangelis G Alexiou
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-07-29       Impact factor: 4.291

2.  New impact factor reflects increased quality.

Authors:  W K Alfred Yung
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

3.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Authors:  Karla V Ballman; Jan C Buckner; Paul D Brown; Caterina Giannini; Patrick J Flynn; Betsy R LaPlant; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2006-11-15       Impact factor: 12.300

4.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Authors:  Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados
Journal:  Neuro Oncol       Date:  2008-03-04       Impact factor: 12.300

5.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.